Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Establishing the link between intestinal metabolites and GvHD risk

Erik Orberg • 12 Dec 2021
ASH 2021
General

Erik Orberg, MD, PhD, University Hospital of the Technical University of Munich, Munich, Germany, discusses the link between the microbiome and graft-versus-host disease (GvHD) in patients undergoing allogeneic stem cell transplantation. The metabolic profile of patients were analyzed and the presence of indole and desaminotyrosine indicated a lower risk of GvHD. The presence of metabolites can additionally stimulate epithelial growth, suggesting the use of metabolites as a prophylactic treatment in patients undergoing transplant. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Erik Orberg

3:25
Impact of microbiome signatures & production of intestinal metabolites on alloSCT outcomes
Erik Orberg • 28 Apr 2023
1:21
Focusing on the fungal and viral microbiome in the transplant setting
Erik Orberg • 12 Dec 2021
2:44
The role of the gut microbiome and metabolome in GvHD susceptibility
Erik Orberg • 12 Dec 2021

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals